Novo Nordisk files for FDA approval of a higher dose of Wegovy® injection 7.2 mg
Novo Nordisk announced the submission of a sNDA to the U.S. Food and Drug Administration (FDA) for a higher dose of semaglutide injection 7.2 mg, to be used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity.
